ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $24.00 Price Target at Stifel Nicolaus

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price decreased by Stifel Nicolaus from $25.00 to $24.00 in a report issued on Thursday,Benzinga reports. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.

ACAD has been the subject of several other research reports. UBS Group upped their target price on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. lowered their price objective on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research report on Monday, November 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research note on Monday, December 29th. Mizuho upgraded shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the company from $29.00 to $35.00 in a research note on Monday. Finally, Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.74.

ACADIA Pharmaceuticals Stock Down 1.3%

ACAD opened at $24.64 on Thursday. ACADIA Pharmaceuticals has a 52-week low of $13.40 and a 52-week high of $28.35. The company has a 50 day moving average of $25.58 and a two-hundred day moving average of $24.45. The company has a market cap of $4.17 billion, a P/E ratio of 10.76, a P/E/G ratio of 8.73 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 13.96%. The business had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. During the same quarter in the previous year, the business posted $0.86 EPS. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Research analysts anticipate that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Buying and Selling

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the firm’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares of the company’s stock, valued at $177,898.42. This trade represents a 47.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Several large investors have recently modified their holdings of ACAD. Farther Finance Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 67.5% in the fourth quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 386 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter worth approximately $26,000. Geneos Wealth Management Inc. grew its position in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 756 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of ACADIA Pharmaceuticals by 107.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 885 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its position in shares of ACADIA Pharmaceuticals by 304.5% during the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 1,005 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations: ACAD reported $1.60 EPS (vs. $0.12 consensus) and $298M revenue, with revenue up ~9% YoY — a clear near-term fundamental positive that supports valuation re-rating. Earnings / Transcript
• Positive Sentiment: Management set 2026 revenue targets of roughly $1.2–$1.28B and highlighted commercial momentum for DAYBUE and NUPLAZID, giving investors a revenue-growth roadmap for next year. Seeking Alpha: 2026 targets
• Positive Sentiment: Multiple analyst actions lifted sentiment — TD Cowen raised its target to $37 (buy), Citizens JMP to $35 (market outperform), and Wolfe Research initiated coverage with an outperform and $33 target — signaling several firms see substantial upside from current levels. Analyst Notes
• Neutral Sentiment: Full earnings materials and call transcript/slide deck are available for detailed review (management commentary covers commercial performance and pipeline updates); useful for investors who want to dig into assumptions behind guidance. Earnings Call Transcript
• Neutral Sentiment: Short-interest reports appearing in data feeds show anomalous zero/NaN values for February; this looks like a reporting glitch and is not a reliable signal of rising short pressure.
• Negative Sentiment: Analysts and headlines flagged an EU setback for trofinetide and a mixed sales read — Zacks notes a sales miss and regulatory/cloud on trofinetide’s EU outlook, which could temper upside for pipeline-derived revenue. Zacks: EU setback
• Negative Sentiment: Some analyst trims introduced headwinds — RBC trimmed its target to $30 and Stifel cut to $24 (hold), creating mixed street sentiment even as other firms raised targets. Analyst Moves
• Negative Sentiment: Broader policy risk for midsize biotechs (debate over MFN / pricing proposals) remains an overhang for the sector and can pressure valuations if regulatory action gains traction. FierceBiotech: Policy risk

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.